News and Trends 12 Oct 2016
Will Aprea live up to the Hype of its €46M fundraising?
Aprea raised a huge €46M for a first-in-class drug that targets the deadliest form of ovarian cancer. The company just started Phase II trials after positive results from Phase I. But will it be able to outperform all its competitors? Aprea is a spin-out company from the Karolinska Development, the portfolio company of the Institute, in Sweden. It became […]
